33342-labeled nuclear DNA were captured with a C-APO 63X/
1.2 W CORR D = 0.28M27 objective with the following filter
sets: exciter BP470/20, dichroic FT 493, emission BP 505–530 for
compromised. Viability assessment was conducted by incubating
cells at 4 ◦C for 1 h with a 1 : 10 mol ratio of protein : carrier,
followed by washing cells with PBS with Ca2+ before imaging of
proteins. Following image capture of the proteins, EthD-1 (1 mM
final concentration) was added and images were recorded at 5,
10, 20 and 30 min using the 630/75 BP filter and revealed no
EthD-1 fluorescence. Cultures were returned to the incubator at
37 ◦C for 17 h before the viability was again evaluated by EthD-1
staining. The morphology of cells monitored by DIC and Hoechst
33342 staining was normal and no EthD-1 uptake into cell nuclei
was detected. Therefore, no cytotoxic effects of protein : carrier
combinations were detected for up to 24 h of cell treatment.
R
Alexa Fluorꢀ 488; exciter BP560/40, dichroic FT 585, emission
R
BP 630/75 for FM 4–64 and BODIPYꢀ TR ceramide complexed
to BSA; and exciter G 365, dichroic FT 395, emission BP 445/50
for Hoechst 33342. Sequential optical sections (Z-stacks) from the
basal-to-apical surfaces of the cell were acquired. Digital image
acquisition was initiated approximately 1 mm below the basal
surface of the cells and optical slices were collected at 0.5 mm
steps through the apical surface of the cells with a high numerical
objective lens (C-APO 63X/1.2 W CORR D = 0.28M27).
These wide-field images were subjected to deconvolution using
3I software.
Flow cytometry
The protein : carrier complexes were pre-formed at room
temperature for 30 min by mixing (in a mol : mol ratio) the
protein and the carrier in DMEM supplemented with 10% fetal
bovine serum (FBS). A 1 : 10 mol : mol ratio of protein : carrier
was used for avidin-F*, BSA-F* and rec. streptavidin-F*, while
a 1 : 20 mol : mol ratio was used for b-gal-F*. To study the
cellular uptake of the proteins, the culture medium was removed,
the preformed protein : carrier complex was added, and the cells
were incubated for another hour at 4 or 37 ◦C. After the incubation
period, the cells were washed with phosphate-buffered saline (PBS,
pH 7.4) several times before imaging. For experiments at 4 ◦C,
cells were preincubated at 4 ◦C for 30 min before being incubated
with the protein solution for 1 h. The cells were also co-stained
with Hoescht (2 mg mL-1), a nuclear marker, and FM 4–64, an
endosome marker.
The protein internalization was measured by flow cytometry on
living cells. COS-7 cells were cultured as subconfluent monolayers
on25cm2 cellcultureplatewithventcaps inDMEMsupplemented
with 10% fetal bovine serum (FBS) in a humidified incubator at
37 ◦C with 5% CO2. Carrier–protein complexes were formed in 1
mL DMEM at a molar protein : carrier ratio of 1 : 10 for avidin
and BSA and 1 : 20 for b-galactosidase and incubated for 30 min
at room temperature. Cells grown to 60–70% confluency were then
overlaid with the preformed complexes and incubated for 1 h at
37 or 4 ◦C. For experiments at 4 ◦C, the cells were preincubated at
4 ◦C for 30 min before addition of the protein–carrier complex.
After 1 h incubation, the cells were washed with PBS, and treated
with trypsin (2 min) and heparin (0.5 mg mL-1 in PBS, 3 ¥ 5 min) to
remove extracellular bound protein. Samples were resuspended in
500 mL PBS and transferred to sterile tubes. Cells were analyzed on
a FACSCalibur (Becton Dickinson Immunocytometry Systems,
San Jose, CA) flow cytometer, equipped with a 15 mW air-cooled
argon laser, using CellQuest (Becton Dickinson) acquisition
Endosomal co-localization
COS-7 cells were incubated with the protein : carrier complex for
1 h at 37 ◦C. After the cells were washed with PBS, FM 4–64 (5◦mg
mL-1) was added and the cells were incubated for 15 min at 37 C.
The cells were washed again with PBS before imaging.
Note: when the cells were co-incubated with the labeled protein
and FM 4–64 for 1 h at 37 ◦C, predominant labeling of the
mitochondria was observed.
R
software. Green fluorescence from Alexa Fluorꢀ 488 or fluorescein
was collected through a 530/30-nm bandpass filter. List mode data
were acquired on a minimum of 10 000 cells or beads defined by
forward and side light scattering light scatter properties. Data
analysis was performed in FlowJo (Treestar, Inc., Ashland, OR),
using forward and side light scatter to gate on cells or single
beads. The Calibrated Parameter platform of FlowJo was used to
determine the molecules of equivalent soluble fluorescein (MESF).
Data are expressed as the median MESF.
Golgi co-localization
After the protein was loaded into the COS-7 cells, the cells were
washed. Then fresh DMEM medium was added, and the cells
R
were incubated with 5 mM of BODIPYꢀ TR ceramide complexed
Acknowledgements
to BSA for 30 min at 4 ◦C. The cells were then rinsed several times
with ice-cold medium and incubated in fresh medium for 30 min
at 37 ◦C. Finally, the cells were washed with PBS before imaging.
We thank the National Institutes of Health (GM72041), the
Robert A. Welch Foundation for financial support, the members
of the TAMU/LBMS-Applications Laboratory directed by Dr
Shane Tichy for assistance with mass spectrometry, and Dr. Roger
Smith (Flow Cytometry Core Laboratory, College of Veterinary
Medicine, Texas A & M University) for the flow cytometry assays.
Viability assay
Theviability of thecells was evaluated bysearchingfor anychanges
in cellular morphology using Nomarski differential interference
contrast (DIC) microscopy during and following analysis of the
cellular uptake of the proteins. Parallel cultures were also evaluated
using DIC microscopy along with fluorescence analysis of the cell-
impermeant viability indicator ethidium homodimer-1 (EthD-1)
(Invitrogen). This high-affinity nucleic acid stain is weakly flu-
orescent until bound to DNA. Unlike Hoechst 33342, EthD-1
can only penetrate cells in which the plasma membrane is
References
1 M. Magzoub and A. Graeslund, Q. Rev. Biophys., 2004, 37, 147–195.
2 H. Brooks, B. Lebleu and E. Vives, Adv. Drug Deliv. Rev., 2005, 57,
559–577.
3 S. Futaki, Adv. Drug Deliv. Rev., 2005, 57, 547–558.
4 M. Kosuge, T. Takeuchi, I. Nakase, A. T. Jones and S. Futaki,
Bioconjugate Chem., 2008, 19, 656–664.
This journal is
The Royal Society of Chemistry 2008
Org. Biomol. Chem., 2008, 6, 4516–4522 | 4521
©